THERAPY DOSSIER · th-9f0c545048e7

Anti-Nogo-A antibody

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 6

2 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT03935321 ↗Injury indicationPHASE2completed

Antibodies against Nogo-A (NG-101) to enhance plasticity and recovery after spinal cord injury

Spinal Cord Injury, Acute

Enrolment: 129 · Results not recorded

NCT00406016 ↗Injury indicationPHASE1completed

Intrathecal ATI355 (anti-Nogo-A) in acute spinal cord injury: safety, tolerability, PK

Acute Spinal Cord Injury

Enrolment: 52 · Results not recorded

NCT01753076 ↗PHASE2completed

Ozanezumab (GSK1223249, anti-Nogo-A) vs placebo in amyotrophic lateral sclerosis

Amyotrophic Lateral Sclerosis

Enrolment: 304 · Results not recorded

NCT00875446 ↗PHASE1completed

Single and repeat dose escalation of GSK1223249 (anti-Nogo-A) in ALS patients

Amyotrophic Lateral Sclerosis

Enrolment: 76 · Results not recorded

NCT01424423 ↗PHASE1terminated

Single ascending dose of GSK1223249 IV in relapsing forms of multiple sclerosis

Multiple Sclerosis

Enrolment: 3 · Results not recorded

NCT01435993 ↗PHASE1terminated

Single/repeat ascending dose of GSK1223249 in relapsing forms of multiple sclerosis

Multiple Sclerosis, Relapsing-Remitting

Enrolment: 3 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 21815784 ↗2011Mixed findings

Delayed anti-nogo-a antibody application after spinal cord injury shows progressive loss of responsiveness.

RatSpinal cord injuryUnspecifiedLewisFemaleIntrathecal infusionAcute, or 1 or 2 weeks delayed

Model: Large incomplete thoracic spinal cord injury

Anti-Nogo-A antibody promoted corticospinal regeneration and functional recovery when given acutely or at 1 week but not at 2 weeks after injury.

Extraction: extract · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.

Loading the evidence…